Weng Miaomiao, Xie Hui, Zheng Mingjie, Hou Xinwen, Wang Shui, Huang Yue
Department of Breast Surgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Department of Clinical Laboratory, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China.
Front Genet. 2022 Sep 30;13:996345. doi: 10.3389/fgene.2022.996345. eCollection 2022.
has been identified as a prognostic biomarker in many neoplasms, but its role in breast cancer (BC) has not been fully explained. We aimed to investigate the molecular mechanism and prognostic value of in BC. expression profile was extracted from TIMER, Oncomine, UALCAN databases, and verified by the Gene Expression Omnibus (GEO) database and quantitative real-time polymerase chain reaction (qRT-PCR). The prognostic value of was assessed GEPIA, Kaplan-Meier plotter and PrognoScan databases. The Cox regression and nomogram analyses were conducted to further validate the association between expression and survival. Gene set enrichment analysis (GSEA), Gene Ontology (GO) analysis, and KEGG pathway enrichment analysis were performed to probe the tumor-associated annotations of . CIBERSORT and ssGSEA were employed to investigate the correlation between expression and immune cell infiltration in BC, and the result was verified by TIMER and TISIDB. Multiple BC cohorts showed that expression was decreased in BC, and a high expression was associated with a preferable prognosis. Therefore, we identified the combined model including , age and PR status to predict the survival (C index = 0.78) of BC patients. Functional enrichment analysis indicated that and its co-expressed genes were closely related to several cancerous and immune signaling pathways, suggesting its involvement in immune response during cancer development. Moreover, immune infiltration analysis revealed that expression was correlated with immune infiltration. Collectively, our findings revealed that may serve as a potential biomarker for favorable prognosis and a promising immune therapeutic target in BC.
已被确定为多种肿瘤的预后生物标志物，但其在乳腺癌（BC）中的作用尚未完全阐明。我们旨在研究其在BC中的分子机制和预后价值。从TIMER、Oncomine、UALCAN数据库中提取其表达谱，并通过基因表达综合数据库（GEO）和定量实时聚合酶链反应（qRT-PCR）进行验证。通过GEPIA、Kaplan-Meier绘图仪和PrognoScan数据库评估其预后价值。进行Cox回归和列线图分析以进一步验证其表达与生存之间的关联。进行基因集富集分析（GSEA）、基因本体（GO）分析和KEGG通路富集分析以探究其肿瘤相关注释。采用CIBERSORT和单样本基因集富集分析（ssGSEA）研究其表达与BC中免疫细胞浸润的相关性，并通过TIMER和TISIDB验证结果。多个BC队列显示其在BC中表达降低，高表达与较好预后相关。因此，我们确定了包括其、年龄和PR状态的联合模型来预测BC患者的生存（C指数=0.78）。功能富集分析表明其及其共表达基因与多种癌症和免疫信号通路密切相关，表明其参与癌症发展过程中的免疫反应。此外，免疫浸润分析显示其表达与免疫浸润相关。总体而言，我们的研究结果表明其可能作为BC中良好预后的潜在生物标志物和有前景的免疫治疗靶点。
